THIRD AMENDMENT TO CREDIT AGREEMENTCredit Agreement • March 18th, 2021 • RedHill Biopharma Ltd. • Pharmaceutical preparations • New York
THIS THIRD AMENDMENT (this “Amendment”) to the Credit Agreement, dated February 23, 2020 (the “Credit Agreement”), among REDHILL BIOPHARMA INC., a Delaware corporation (the “Borrower”), REDHILL BIOPHARMA LTD., a company incorporated under the laws of the State of Israel, as Guarantor (“Parent”), the Lenders (defined therein), HCR Collateral Management, LLC (“Agent” and together with the Borrower, Parent, the Lenders and Agent, the “Parties”), as Administrative Agent and those additional entities that hereafter become parties hereto in accordance with the terms hereof by executing a Joinder Agreement, is executed as of January 28, 2021 (the “Effective Date”). Capitalized terms not otherwise defined herein have the same meaning as in the Credit Agreement (and all rules governing terminology or interpretation set forth in the Credit Agreement are hereby incorporated by reference).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 18th, 2021 • RedHill Biopharma Ltd. • Pharmaceutical preparations • New York
THIS SECURITIES PURCHASE AGREEMENT (“Agreement”) is made and entered into as of August 3, 2020 (the “Signing Date”), by and between RedHill Biopharma Ltd., a company limited by shares organized under the laws of the State of Israel (the “Company”), and Daiichi Sankyo, Inc., a Delaware corporation (“Daiichi Sankyo”). The Company and Daiichi Sankyo shall be referred to individually each as a “Party” and collectively as the “Parties.”
CERTAIN IDENTIFIED INFORMATION MARKED [***] HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. Amendment No. 3 to License AgreementLicense Agreement • March 18th, 2021 • RedHill Biopharma Ltd. • Pharmaceutical preparations
This Amendment No. 3 to the License Agreement, dated as of October 6, 2020 (this “Amendment”), is made by and between AstraZeneca AB (“AstraZeneca”) and RedHill Biopharma Inc. (“Licensee”), each individually a “Party” and collectively, the “Parties”.
SECOND AMENDMENT TO CREDIT AGREEMENTCredit Agreement • March 18th, 2021 • RedHill Biopharma Ltd. • Pharmaceutical preparations • New York
THIS SECOND AMENDMENT (this “Amendment”) to the Credit Agreement, dated February 23, 2020 (the “Credit Agreement”), among REDHILL BIOPHARMA INC., a Delaware corporation (the “Borrower”), REDHILL BIOPHARMA LTD., a company incorporated under the laws of the State of Israel, as Guarantor (“Parent”), the Lenders (defined therein), HCR Collateral Management, LLC (“Agent” and together with the Borrower, Parent, the Lenders and Agent, the “Parties”), as Administrative Agent and those additional entities that hereafter become parties hereto in accordance with the terms hereof by executing a Joinder Agreement, is executed as of August 12, 2020 (the “Effective Date”). Capitalized terms not otherwise defined herein have the same meaning as in the Credit Agreement (and all rules governing terminology or interpretation set forth in the Credit Agreement are hereby incorporated by reference).
CERTAIN IDENTIFIED INFORMATION MARKED [***] HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. Amendment No. 1 to License AgreementLicense Agreement • March 18th, 2021 • RedHill Biopharma Ltd. • Pharmaceutical preparations
This Amendment No. 1 to the License Agreement, dated as of March 31, 2020 (this “Amendment”), is made by and between AstraZeneca AB (“AstraZeneca”) and RedHill Biopharma Inc. (“Licensee”), each individually a “Party” and collectively, the “Parties”.
CERTAIN IDENTIFIED INFORMATION MARKED [***] HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. TERMINATION AGREEMENTTermination Agreement • March 18th, 2021 • RedHill Biopharma Ltd. • Pharmaceutical preparations • New York
This Termination Agreement (this “Termination Agreement”) is made and entered into on August 3, 2020 but effective as of July 1, 2020 (the “Termination Effective Date”) by and between REDHILL BIOPHARMA, INC., a company organized under the laws of the state of Delaware (“RedHill”), and DAIICHI SANKYO, INC., a company organized under the laws of the state of Delaware (“Daiichi Sankyo”). Each of RedHill and Daiichi Sankyo is referred to individually as a “Party” and collectively as the “Parties.”
CERTAIN IDENTIFIED INFORMATION MARKED [***] HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. Amendment No. 4 to License AgreementLicense Agreement • March 18th, 2021 • RedHill Biopharma Ltd. • Pharmaceutical preparations
This Amendment No. 4 to the License Agreement, dated as of March 11th, 2021 (this “Amendment”), is made by and between AstraZeneca AB (“AstraZeneca”) and RedHill Biopharma Inc. (“Licensee”), each individually a “Party” and collectively, the “Parties”.
FIRST AMENDMENT TO CREDIT AGREEMENTCredit Agreement • March 18th, 2021 • RedHill Biopharma Ltd. • Pharmaceutical preparations • New York
THIS FIRST AMENDMENT TO CREDIT AGREEMENT (this “Amendment”), dated as of March 31, 2020 (the “Amendment Effective Date”), is made by and among REDHILL BIOPHARMA INC., a Delaware corporation (the “Borrower”), REDHILL BIOPHARMA LTD., a company incorporated under the laws of the State of Israel, as Guarantor (“RedHill Parent”), the Lenders (defined in the Credit Agreement), HCR COLLATERAL MANAGEMENT, LLC, as Administrative Agent (“Agent”) and those additional entities that hereafter become parties to the Credit Agreement in accordance with the terms thereof by executing a Joinder Agreement.
CERTAIN IDENTIFIED INFORMATION MARKED [***] HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. Amendment No. 2 to License AgreementLicense Agreement • March 18th, 2021 • RedHill Biopharma Ltd. • Pharmaceutical preparations
This Amendment No. 2 to the License Agreement, dated as of July 14, 2020 (this “Amendment”), is made by and between AstraZeneca AB (“AstraZeneca”) and RedHill Biopharma Inc. (“Licensee”), each individually a “Party” and collectively, the “Parties”.
